NVO compared with PFE: revenue, margins and what each company keeps, and the suppliers and customers both name

NVONovo Nordisk A S

Mkt capRevenueRevenue

PFEPfizer Inc

Mkt capRevenueRevenue

Compare

NVONovo Nordisk A S

PFEPfizer Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

NVO: latest quarter not drawable.Method ›

Price

rebased to 0%

NVO, solidPFE, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NVO 6

OMEROmerossupplier

LXRXLexicon Pharmaceuticalssupplier

COAGHemab Therapeuticscustomer

VTVTvTv Therapeuticscustomer

2 more · NVO chain ›

Shared 0

No shared counterparties.

Only PFE 34

MIRMMirum Pharmaceuticalscustomer

ICUIICU Medicalcustomer

BEAMBeam Therapeuticssupplier

ADPTAdaptive Biotechnologiessupplier

Role chip = supplier or customerSource: SEC EDGAR

30 more · PFE chain ›

NVONovo Nordisk A S

40.27▼−0.08%· post 40.31

Mkt cap$180.0BRevenue—Revenue—

PFEPfizer Inc

29.39▼−0.21%· post 29.35

ClosedNov 6 '26

Mkt cap$167.5BRevenue$16.6BQ3 FY26Revenue$62.6BFY25

Compare

ClosedNov 6 '26

NVONovo Nordisk A S

PFEPfizer Inc

40.27▼−0.08%post 40.31

Price

29.39▼−0.21%post 29.35

$180.0B

Mkt cap

$167.5B

—

Revenue

$16.6BQ3 FY26

—

Revenue

$62.6BFY25

NVO40.27▼−0.08%vsPFE29.39▼−0.21%ClosedNov 6 '26